<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Healthcare on FinanClub</title>
    <link>https://finan.club/tags/healthcare/</link>
    <description>Recent content in Healthcare on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 23 Feb 2024 09:03:07 +0000</lastBuildDate><atom:link href="https://finan.club/tags/healthcare/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AGL</title>
      <link>https://finan.club/us/agl/</link>
      <pubDate>Fri, 23 Feb 2024 09:03:07 +0000</pubDate>
      
      <guid>https://finan.club/us/agl/</guid>
      <description>score:-37
Chances: Agilon Health, Inc. is participating in the 44th Annual Cowen Health Care Conference, indicating its commitment to engaging with investors and stakeholders. The company&amp;rsquo;s focus on providing healthcare for seniors through a Total Care Model presents a significant opportunity in the growing Medicare market.</description>
    </item>
    
    <item>
      <title>ALKS</title>
      <link>https://finan.club/us/alks/</link>
      <pubDate>Fri, 16 Feb 2024 09:02:33 +0000</pubDate>
      
      <guid>https://finan.club/us/alks/</guid>
      <description>score:-21
Chances: Alkermes stock saw its Relative Strength Rating improve from 69 to 75, indicating a potential rebound in the stock&amp;rsquo;s performance. The company&amp;rsquo;s earnings and revenues outpaced estimates in the fourth quarter of 2023, driven by strong growth in proprietary products. Robust revenue growth and strategic focus are likely to propel Alkermes into 2024, indicating positive prospects for the company.</description>
    </item>
    
    <item>
      <title>ORCL</title>
      <link>https://finan.club/us/orcl/</link>
      <pubDate>Mon, 12 Feb 2024 09:12:00 +0000</pubDate>
      
      <guid>https://finan.club/us/orcl/</guid>
      <description>score:231
Chances: Oracle (ORCL) has been recognized as a Leader in the IDC MarketScape: U.S. Electronic Health Record (EHR) 2023-2024 Vendor Assessment, indicating potential for growth in the healthcare sector. Leading healthcare organizations are implementing Oracle Fusion Cloud Applications Suite, suggesting a potential increase in customer base and revenue.</description>
    </item>
    
    <item>
      <title>WBA</title>
      <link>https://finan.club/us/wba/</link>
      <pubDate>Fri, 09 Feb 2024 09:04:42 +0000</pubDate>
      
      <guid>https://finan.club/us/wba/</guid>
      <description>score:60
Chances: Walgreens Boots Alliance has made strategic executive appointments and updates to its healthcare and retail pharmacy services, indicating a proactive approach to turning around its stock performance. The company&amp;rsquo;s focus on its healthcare segment and cost structure alignment demonstrates a commitment to improving business performance and addressing waning demand for certain products.</description>
    </item>
    
    <item>
      <title>ABT</title>
      <link>https://finan.club/us/abt/</link>
      <pubDate>Thu, 01 Feb 2024 09:07:36 +0000</pubDate>
      
      <guid>https://finan.club/us/abt/</guid>
      <description>score:53
Chances: Abbott Laboratories is launching new products in response to high demand for weight-loss drugs, indicating a potential growth opportunity in the healthcare space. The company&amp;rsquo;s Protality brand, including a high-protein shake, is a strategic move to capitalize on the surge in demand for weight-loss products.</description>
    </item>
    
    <item>
      <title>JNJ</title>
      <link>https://finan.club/us/jnj/</link>
      <pubDate>Wed, 24 Jan 2024 09:08:15 +0000</pubDate>
      
      <guid>https://finan.club/us/jnj/</guid>
      <description>score:51
Chances: Johnson &amp;amp; Johnson beat fourth-quarter expectations with strong performance in the medtech segment. The company reported adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus. Sales increased by 7.3% year-over-year to $21.4 billion, surpassing the consensus. Risks: Johnson &amp;amp; Johnson&amp;rsquo;s stock tumbled after the company reported lower profit margins in the medical device and technology unit last quarter.</description>
    </item>
    
    <item>
      <title>KVUE</title>
      <link>https://finan.club/us/kvue/</link>
      <pubDate>Fri, 12 Jan 2024 09:06:15 +0000</pubDate>
      
      <guid>https://finan.club/us/kvue/</guid>
      <description>score:39
Chances: Kenvue Inc. is poised to benefit from the favorable court ruling in a product-liability case, which has resulted in a nearly 5% increase in the company&amp;rsquo;s stock price. The Self Care segment, including cough, cold and allergy, pain care, digestive health, and smoking cessation, presents a strong opportunity for growth and revenue generation.</description>
    </item>
    
    <item>
      <title>GDRX</title>
      <link>https://finan.club/us/gdrx/</link>
      <pubDate>Thu, 11 Jan 2024 09:04:35 +0000</pubDate>
      
      <guid>https://finan.club/us/gdrx/</guid>
      <description>score:82
Chances: Shares of GoodRx (GDRX) popped after reporting upbeat preliminary fourth quarter and full year 2023 results. GoodRx unveiled preliminary fourth-quarter revenue that topped analysts&amp;rsquo; estimates. The company has seen &amp;ldquo;great demand&amp;rdquo; for its products, indicating potential growth opportunities. Risks: The company operates in the highly competitive healthcare industry.</description>
    </item>
    
    <item>
      <title>CLVT</title>
      <link>https://finan.club/us/clvt/</link>
      <pubDate>Tue, 09 Jan 2024 09:07:33 +0000</pubDate>
      
      <guid>https://finan.club/us/clvt/</guid>
      <description>score:-7
Chances: Clarivate Plc has been consistently releasing new reports and products, indicating a strong focus on innovation and meeting the evolving needs of the healthcare and research industries. Risks: The company operates in a highly competitive market, and its success depends on the adoption of its products and solutions by academia, government, life sciences, and healthcare organizations.</description>
    </item>
    
    <item>
      <title>HIMS</title>
      <link>https://finan.club/us/hims/</link>
      <pubDate>Wed, 03 Jan 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/hims/</guid>
      <description>score:108
Chances: Hims &amp;amp; Hers Health, Inc. unveiled Weight Loss by Hims &amp;amp; Hers, a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals. The company has appointed Craig Primack, a pioneer in the field of clinical obesity medicine, as SVP of Weight Management, indicating a strong focus on addressing the growing issue of obesity.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
